Treatment of malignant Leydig cell tumor.
Malignant Leydig cell tumors (LCT) are rare. Only 32 cases of malignant LCT (as evidenced by metastatic spread) were reported. Generally metastatic spread occurs within 2 years of the primary LCT, and the patient dies within 2 years of the discovery of metastatic disease. The tumor is highly resistant to both radiation and chemotherapy. It also has a great propensity for recurring after surgical resection. A case is reported of a patient whose metastatic disease occurred 8 years after his primary LCT had been resected. He was treated with doxorubicin and mitotane without response. The clinical features of this case are highlighted, and a review of the literature describing treatment of this rare disease is presented.
Bertram
K A
KA
Department of Medical Oncology, Madigan Army Medical Center, Tacoma, Washington 98431.
Bratloff
B
B
Hodges
G F
GF
Davidson
H
H
D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D007984:Leydig Cell Tumor / Q000556:secondary* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D008939:Mitotane / Q000627:therapeutic use; D012186:Retroperitoneal Neoplasms / Q000188:drug therapy / Q000556:secondary*; D013736:Testicular Neoplasms / Q000473:pathology
D008939:Mitotane; D004317:Doxorubicin